• Je něco špatně v tomto záznamu ?

IgA nephropathy: the lectin pathway and implications for targeted therapy

J. Barratt, RA. Lafayette, H. Zhang, V. Tesar, BH. Rovin, JA. Tumlin, HN. Reich, J. Floege

. 2023 ; 104 (2) : 254-264. [pub] 20230530

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016729

Many patients with immunoglobulin A nephropathy (IgAN) progress to kidney failure even with optimal supportive care. An improved understanding of the pathophysiology of IgAN in recent years has led to the investigation of targeted therapies with acceptable tolerability that may address the underlying causes of IgAN or the pathogenesis of kidney injury. The complement system-particularly the lectin and alternative pathways of complement-has emerged as a key mediator of kidney injury in IgAN and a possible target for investigational therapy. This review will focus on the lectin pathway. The examination of kidney biopsies has consistently shown glomerular deposition of mannan-binding lectin (1 of 6 pattern-recognition molecules that activate the lectin pathway) together with IgA1 in up to 50% of patients with IgAN. Glomerular deposition of pattern-recognition molecules for the lectin pathway is associated with more severe glomerular damage and more severe proteinuria and hematuria. Emerging research suggests that the lectin pathway may also contribute to tubulointerstitial fibrosis in IgAN and that collectin-11 is a key mediator of this association. This review summarizes the growing scientific and clinical evidence supporting the role of the lectin pathway in IgAN and examines the possible therapeutic role of lectin pathway inhibition for these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016729
003      
CZ-PrNML
005      
20231026105610.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.kint.2023.04.029 $2 doi
035    __
$a (PubMed)37263354
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Barratt, Jonathan $u Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
245    10
$a IgA nephropathy: the lectin pathway and implications for targeted therapy / $c J. Barratt, RA. Lafayette, H. Zhang, V. Tesar, BH. Rovin, JA. Tumlin, HN. Reich, J. Floege
520    9_
$a Many patients with immunoglobulin A nephropathy (IgAN) progress to kidney failure even with optimal supportive care. An improved understanding of the pathophysiology of IgAN in recent years has led to the investigation of targeted therapies with acceptable tolerability that may address the underlying causes of IgAN or the pathogenesis of kidney injury. The complement system-particularly the lectin and alternative pathways of complement-has emerged as a key mediator of kidney injury in IgAN and a possible target for investigational therapy. This review will focus on the lectin pathway. The examination of kidney biopsies has consistently shown glomerular deposition of mannan-binding lectin (1 of 6 pattern-recognition molecules that activate the lectin pathway) together with IgA1 in up to 50% of patients with IgAN. Glomerular deposition of pattern-recognition molecules for the lectin pathway is associated with more severe glomerular damage and more severe proteinuria and hematuria. Emerging research suggests that the lectin pathway may also contribute to tubulointerstitial fibrosis in IgAN and that collectin-11 is a key mediator of this association. This review summarizes the growing scientific and clinical evidence supporting the role of the lectin pathway in IgAN and examines the possible therapeutic role of lectin pathway inhibition for these patients.
650    _2
$a lidé $7 D006801
650    12
$a IgA nefropatie $x patologie $7 D005922
650    _2
$a lektiny $x metabolismus $7 D037102
650    _2
$a glomerulus $x patologie $7 D007678
650    _2
$a ledviny $x patologie $7 D007668
650    _2
$a imunoglobulin A $x metabolismus $7 D007070
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Lafayette, Richard A $u Department of Medicine, Division of Nephrology, Stanford Health Care, Stanford, California, USA
700    1_
$a Zhang, Hong $u Renal Division, Department of Internal Medicine, Peking University Institute of Nephrology, Beijing, China
700    1_
$a Tesar, Vladimir $u Department of Nephrology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Rovin, Brad H $u Department of Internal Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
700    1_
$a Tumlin, James A $u Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, Georgia, USA
700    1_
$a Reich, Heather N $u Department of Medicine, Division of Nephrology, University of Toronto and University Health Network, Toronto, Ontario, Canada
700    1_
$a Floege, Jürgen $u Department of Nephrology and Rheumatology, RWTH Aachen University Hospital, Aachen, Germany. Electronic address: jfloege@ukaachen.de
773    0_
$w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 104, č. 2 (2023), s. 254-264
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37263354 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105605 $b ABA008
999    __
$a ok $b bmc $g 2000319 $s 1203091
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 104 $c 2 $d 254-264 $e 20230530 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace